Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531641 | 1.00 | MMP2 (0.58) | MMP2ERAP2LNPEPPSMB1PSMB8 | |
| SCHEMBL30434967 | 0.93 | MMP2 (0.51) | MMP2ERAP2LNPEPPSMB1PSMB8 | |
| SCHEMBL7872647 | 0.91 | OPRD1 (0.56) | MMP2OPRK1 | |
| SCHEMBL7872640 | 0.91 | OPRD1 (0.56) | MMP2OPRK1 | |
| SCHEMBL31253360 | 0.91 | LNPEP (0.56) | MMP2ERAP2LNPEPOPRK1 | |
| SCHEMBL29424183 | 0.91 | MMP2 (0.61) | MMP2ERAP2LNPEPOPRK1 | |
| SCHEMBL30478748 | 0.89 | MMP2 (0.55) | MMP2OPRK1 | |
| SCHEMBL13167829 | 0.88 | MMP2 (0.53) | MMP2ERAP2LNPEPPSMB1PSMB8 | |
| SCHEMBL29403606 | 0.86 | SLC15A1 (0.54) | OPRK1CTSC | |
| SCHEMBL29630365 | 0.86 | ERAP2 (0.62) | MMP2ERAP2LNPEPOPRK1CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-4484446-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2025-01-01 | — | — | EP | claimed |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-12-12 | — | — | US | claimed |
| EP-4410372-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2024-08-07 | — | — | EP | claimed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| WO-2023160651-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-08-31 | — | — | WO | claimed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | claimed |
| WO-2023046202-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2023-03-30 | — | — | WO | claimed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | EVOPOINT BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| US-12435143-B2 | Caninized antibodies against canine CTLA-4 | INTERVET INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250135018-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4484446-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| EP-4103236-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220378924-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220251208-A1 | Caninized Antibodies Against Canine CTLA-4 | INTERVET INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022093793-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378924-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | MMP2 3473/4885ERAP2 2630/4885LNPEP 187/4885 |
| US-20250333541-A1 | ANTIBODY, AND DRUG CONJUGATE AND USE THEREOF | TNFRSF9, F13B, FCGR1A | MMP2 446/4885ERAP2 1982/4885LNPEP 240/4885 |
| US-20240409628-A1 | ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | EPCAM, CNTN1, STX18 | MMP2 2145/4885ERAP2 3249/4885LNPEP 437/4885 |
| US-20250135018-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | MMP2 2821/4885ERAP2 2132/4885LNPEP 207/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | MMP2 1751/4885ERAP2 4021/4885LNPEP 221/4885 |
| US-20220193069-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | MMP2 2821/4885ERAP2 2132/4885LNPEP 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.